Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $65.00 at Wedbush

Beam Therapeutics (NASDAQ:BEAM) had its price target hoisted by Wedbush from $57.00 to $65.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other brokerages have also issued reports on BEAM. Sanford C. Bernstein boosted their price objective on Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, January 21st. Benchmark reissued a “speculative buy” rating on shares of Beam Therapeutics in a research report on Monday, November 17th. UBS Group initiated coverage on shares of Beam Therapeutics in a research report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price objective on the stock. Finally, Tudor Pickering set a $41.00 target price on Beam Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Beam Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $46.19.

Beam Therapeutics Stock Down 8.3%

Shares of BEAM stock opened at $29.61 on Wednesday. Beam Therapeutics has a 12-month low of $13.52 and a 12-month high of $36.44. The firm has a fifty day moving average of $28.82 and a 200-day moving average of $25.02. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -29.32 and a beta of 2.12.

Beam Therapeutics (NASDAQ:BEAM) last posted its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share for the quarter, topping the consensus estimate of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 32.06% and a negative net margin of 57.24%.The firm had revenue of $114.11 million for the quarter, compared to analyst estimates of $13.22 million. During the same period in the previous year, the company posted ($1.09) earnings per share. The company’s revenue for the quarter was up 280.3% on a year-over-year basis. Research analysts expect that Beam Therapeutics will post -4.57 earnings per share for the current year.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 1,371 shares of the stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $34.00, for a total value of $46,614.00. Following the completion of the sale, the insider owned 95,667 shares in the company, valued at $3,252,678. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds have recently bought and sold shares of BEAM. CWM LLC increased its position in Beam Therapeutics by 15.4% during the fourth quarter. CWM LLC now owns 2,466 shares of the company’s stock worth $68,000 after buying an additional 329 shares during the last quarter. Wealth Effects LLC increased its holdings in shares of Beam Therapeutics by 4.3% during the 4th quarter. Wealth Effects LLC now owns 9,600 shares of the company’s stock worth $266,000 after acquiring an additional 400 shares during the last quarter. Franklin Resources Inc. raised its stake in Beam Therapeutics by 2.6% in the 4th quarter. Franklin Resources Inc. now owns 21,948 shares of the company’s stock valued at $608,000 after acquiring an additional 566 shares during the period. Arizona State Retirement System raised its stake in Beam Therapeutics by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock valued at $650,000 after acquiring an additional 580 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after purchasing an additional 707 shares during the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam reported a blowout Q4: $2.33 EPS vs. consensus of -$1.13 and revenue of $114.1M vs. ~$13M expected — results materially beat street estimates and show strong year‑over‑year revenue growth. Press Release / Results
• Positive Sentiment: Beam secured a $500M strategic financing facility with Sixth Street ($100M funded at close, up to $400M available) — long‑dated, non‑dilutive capital to support a potential launch (extends cash runway). Financing Announcement
• Positive Sentiment: Pfizer locked a global license for one of Beam’s gene‑editing candidates after exiting a gene therapy program — validates partnering interest and external commercialization potential. FierceBiotech Article
• Positive Sentiment: Wedbush raised its price target to $65 and kept an outperform rating — a bullish analyst call that signals upside from current levels. Wedbush / Coverage
• Neutral Sentiment: Beam announced a new liver‑targeted program for PKU and expects an IND for BEAM‑304 in 2026 — a constructive R&D development but early‑stage and not an immediate revenue driver. GenEngNews on PKU program
• Neutral Sentiment: Multiple earnings summaries and the full call transcript are available for deeper read — useful for investors assessing sustainability of revenue and margins. Earnings Call Summary
• Negative Sentiment: RBC raised its target to $26 but kept a “sector perform” rating — that target implies downside vs. current levels and may encourage some selling or limit upside momentum. The Fly / RBC Note
• Negative Sentiment: Despite strong fundamentals, short‑term price weakness appears driven by profit‑taking and mixed analyst views; coverage pieces asking “what’s going on” reflect near‑term uncertainty among traders. MSN Coverage

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.